17 July 2019: Cancer Alliance submits a motivation to SAHPRA for the prompt approval of trastuzumab biosimilars to promote competition in the market.
The Cancer Alliance of South Africa submits this memorandum in support of its request that SAHPRA promptly register biosimilars of the breast cancer medicine trastuzumab
for which manufacturers have submitted New Medicine Launch Forms. We commend SAHPRA for recently approving Mylan’s biosimilar and stress the importance of swiftly
approving the four remaining applications submitted by other trastuzumab biosimilar manufacturers.
Read the full report: